Weight-sparing effect of insulin detemir: A consequence of central nervous system-mediated reduced energy intake?

Diabetes, Obesity and Metabolism

Volumn 17, Issue 10, 2015, Pages 919-927

  Russell Jones, D ^a   Danne, T ^b   Hermansen, K ^c   Niswender, K ^d   Robertson, K ^e   Thalange, N ^f   Vasselli, J R ^g   Yildiz, B ^h   Haring H U ⁱ  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^b KINDERKRANKENHAUS AUF DER BULT   (Germany)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^f NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h HACETTEPE UNIVERSITY   (Turkey)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Basal insulin; Drug mechanism; Weight loss therapy

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

BODY WEIGHT; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN METABOLISM; CALORIC INTAKE; CALORIMETRY; CARBOHYDRATE INTAKE; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; DRUG WEIGHT SPARING EFFECT; ELECTROENCEPHALOGRAM; ENERGY BALANCE; ENERGY EXPENDITURE; FAT INTAKE; FAT MASS; FLUID RETENTION; FOOD INTAKE; FRONTAL CORTEX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLOMERULUS FILTRATION RATE; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; HYPOTHALAMUS; INSULIN SIGNALING; INSULIN TREATMENT; LIVER METABOLISM; LOW DRUG DOSE; NEUROIMAGING; NEUROMODULATION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN INTAKE; REVIEW; SIGNAL TRANSDUCTION; WEIGHT GAIN; DIABETES MELLITUS; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; KIDNEY; LIVER; METABOLISM;

BLOOD GLUCOSE; BODY WEIGHT; CENTRAL NERVOUS SYSTEM; DIABETES MELLITUS; ENERGY INTAKE; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN DETEMIR; KIDNEY; LIVER; WEIGHT GAIN;

EID: 84942294471     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12493     Document Type: Review

References (69)

1. American Diabetes Association. Standards of medical care in diabetes - 2014. Diabetes Care 2014; 37: S14-80.
2. Bryden KS, Neil A, Mayou RA etal. Eating habits, body weight, and insulin misuse: a longitudinal study of teenagers and young adults with type 1 diabetes. Diabetes Care 1999; 22: 1956-1960.
3. Eeg-Olofsson K, Cederholm J, Nilsson PM etal. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13, 087 patients. Diabetologia 2009; 52: 65-73.
4. Purnell JQ, Hokanson JE, Marcovina SM etal. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998; 280: 140-146.
5. Norris SL, Zhang X, Avenell A etal. Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis. Am J Med 2004; 117: 762-774.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1988; 352: 837-853.
7. The DCCT Group. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes Care 1988; 11: 567-573.
8. Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res 2008; 6: 54-67.
9. Frier BM, Russell-Jones D, Heise T. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Diabetes Obes Metab 2013; 15: 978-986.
10. Swinnen SG, Simon AC, Holleman F etal. Insulin detemir versus insulin glargine for type 2 diabetes. Cochrane Database Syst Rev 2011 (7): CD006383.
11. Heinemann L, Sinha K, Weyer C etal. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 1999; 16: 332-338.
12. Robertson KJ, Schoenle E, Gucev Z etal. Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med 2007; 24: 27-34.
13. Thalange N, Bereket A, Larsen J etal. Insulin analogues in children with type 1 diabetes: a 52-week randomized clinical trial. Diabet Med 2013; 30: 216-225.
14. Zinman B, Philis-Tsimikas A, Cariou B etal. Insulin degludec versus insulin glargine in insulin-naïve patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012; 35: 2464-2471.
15. Kurtzhals P, Havelund S, Jonassen I etal. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995; 312: 725-731.
16. Kurtzhals P, Schäffer L, Sorensen A etal. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.
17. Davies MJ, Derezinski T, Pedersen CB etal. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technol Ther 2008; 10: 273-277.
18. Vasselli JR, Currie PJ, Pi-Sunyer FX. Glycemic basis for reduced feeding by intact and diabetic rats in response to injections of insulin detemir. Diabetologia 2009; 52(Suppl. 1): A501, 201.
19. Rojas JM, Printz RL, Niswender KD. Insulin detemir attenuates food intake, body weight gain and fat mass gain in diet-induced obese Sprague-Dawley rats. Nutr Diabetes 2011; 1: e10.
20. Zafar MI, Hu C, Liu D etal. Insulin detemir causes lesser weight gain in comparison to insulin glargine: role on hypothalamic NPY and galanin. J Diabetes Res 2014; 2014: 458104.
21. Kanarek RB, Marks-Kaufman R, Lipeles BJ. Increased carbohydrate intake as a function of insulin administration in rats. Physiol Behav 1980; 25: 779-782.
22. Brandes JS. Insulin induced overeating in the rat. Physiol Behav 1977; 18: 1095-1102.
23. Larue-Achagiotis C, Goubern M, Laury MC. Concomitant food intake and adipose tissue responses under chronic insulin infusion in rats. Physiol Behav 1988; 44: 95-100.
24. Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 2007; 9: 209-217.
25. Dornhorst A, Lüddeke HJ, Sreenan S etal. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract 2008; 62: 659-665.
26. Zachariah S, Sheldon B, Shojaee-Moradie F etal. Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes. Diabetes Care 2011; 34: 1487-1491.
27. Pieber TR, Draeger E, Kristensen A etal. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005; 22: 850-857.
28. De Leeuw I, Vague P, Selam JL etal. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7: 73-82.
29. Russell-Jones D, Simpson R, Hylleberg B etal. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. J Clin Ther 2004; 26: 724-736.
30. Standl E, Lang H, Roberts A etal. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 2004; 6: 579-588.
31. Whitcomb DC, Puccio AM, Vigna SR etal. Distribution of pancreatic polypeptide receptors in the rat brain. Brain Res 1997; 760: 137-149.
32. Bruning JC, Gautam D, Burks DJ etal. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289: 2122-2125.
33. Obici S, Zhang BB, Karkanias G etal. Hypothalamic insulin signalling is required for inhibition of glucose production. Nat Med 2002; 8: 1376-1382.
34. Air EL, Benoit SC, Blake Smith KA etal. Acute third ventricular administration of insulin decreases food intake in two paradigms. Pharmacol Biochem Behav 2002; 72: 423-429.
35. Posey KA, Clegg DJ, Printz RL etal. Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet. Am J Physiol Endocrinol Metab 2009; 296: E1003-1012.
36. Heni M, Kullmann S, Ketterer C etal. Nasal insulin changes peripheral insulin sensitivity simultaneously with altered activity in homeostatic and reward-related human brain regions. Diabetologia 2012; 55: 1773-1782.
37. Heni M, Wagner R, Kullmann S etal. Central insulin administration improves whole-body insulin sensitivity via hypothalamus and parasympathetic outputs in men. Diabetes 2014; 63: 4083-4088.
38. Benedict C, Hallschmid M, Hatke A etal. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004; 29: 1326-1334.
39. Hallschmid M, Benedict C, Schultes B etal. Intranasal insulin reduces body fat in men but not in women. Diabetes 2004; 53: 3024-3029.
40. Hallschmid M, Higgs S, Thienel M etal. Postprandial administration of intranasal insulin intensifies satiety and reduces intake of palatable snacks in women. Diabetes 2012; 61: 782-789.
41. Hennige AM, Sartorius T, Tschritter O etal. Tissue selectivity of insulin detemir action in vivo. Diabetologia 2006; 49: 1274-1282.
42. Lin X, Taguchi A, Park S etal. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J Clin Invest 2004; 114: 908-916.
43. Begg DP, May AA, Mul D etal. Insulin detemir is transported from blood to cerebrospinal fluid and has prolonged central anorectic action relative to NPH insulin. Diabetes 2015; 64: 2457-2466.
44. Banks WA, Morley JE, Lynch JL etal. Insulin detemir is not transported across the blood-brain barrier. Peptides 2010; 31: 2284-2288.
45. Vasselli JR, Wall D, John C etal. Reduction of food intake and body weight by central administration of insulin detemir in rats. Diabetes 2009; 58(Suppl. 1): A1533, 396.
46. Moore MC, Smith MS, Turney MK etal. Comparison of insulins detemir and glargine: effects on glucose disposal, hepatic glucose release and the central nervous system. Diabetes Obes Metab 2011; 13: 832-840.
47. Takei N, Furukawa K, Hanyu O etal. A possible link between BDNF and mTOR in control of food intake. Front Psychol 2014; 5: 1093.
48. Woods SC, Seeley RJ. Insulin as an adiposity signal. Int J Obes Relat Metab Disord 2001; 25(Suppl. 5): S35-38.
49. Tschritter O, Preissl H, Hennige AM etal. The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study. Proc Natl Acad Sci U S A 2006; 103: 12103-12108.
50. Tschritter O, Hennige AM, Preissl H etal. Cerebrocortical beta activity in overweight humans responds to insulin detemir. PLoS One 2007; 2: e1196.
51. Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 2011; 60: 2441-2449.
52. Tschritter O, Preissl H, Hennige AM etal. The insulin effect on cerebrocortical theta activity is associated with serum concentrations of saturated nonesterified fatty acids. J Clin Endocrinol Metab 2009; 94: 4600-4607.
53. Sartorius T, Ketterer C, Kullmann S etal. Monounsaturated fatty acids prevent the aversive effects of obesity on locomotion, brain activity, and sleep behaviour. Diabetes 2012; 61: 1669-1679.
54. Hallschmid M, Jauch-Chara K, Korn O etal. Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects. Diabetes 2010; 59: 1101-1107.
55. Van Golen LW, Ijzerman RG, Huisman MC etal. Cerebral blood flow and glucose metabolism in appetite-related brain regions in type 1 diabetic patients after treatment with insulin detemir and NPH insulin. Diabetes Care 2013; 36: 4050-4056.
56. DelParigi A, Chen K, Salbe AD etal. Successful dieters have increased neural activity in cortical areas involved in the control of behavior. Int J Obes (Lond) 2007; 31: 440-448.
57. Val-Laillet D, Layec S, Guérin S etal. Changes in brain activity after a diet-induced obesity. Obesity (Silver Spring) 2011; 19: 749-756.
58. Hirvonen J, Virtanen KA, Nummenmaa L etal. Effects of insulin on brain glucose metabolism in impaired glucose tolerance. Diabetes 2011; 60: 443-444.
59. Van Golen LW, Veltman DJ, Ijzerman RG etal. Effects of insulin detemir and NPH insulin on body weight and appetite-regulating brain regions in human type 1 diabetes: a randomized controlled trial. PLoS One 2014; 9: e94483.
60. Bruce AS, Holsen LM, Chambers RJ etal. Obese children show hyperactivation to food pictures in brain networks linked to motivation, reward and cognitive control. Int J Obes 2010; 34: 1494-1500.
61. Murdaugh DL, Cox JE, Cook EW III etal. fMRI reactivity to high-calorie food pictures predicts short- and long-term outcome in a weight-loss program. Neuroimage 2012; 59: 2709-2721.
62. Hordern SV, Wright JE, Umpleby AM etal. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia 2005; 48: 420-426.
63. Smeeton F, Shojaee Moradie F, Jones RH etal. Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes. Diabetologia 2009; 52: 2317-2323.
64. Chap Z, Ishida T, Chan J etal. First pass extraction and metabolic effects of insulin and insulin analogues. Am J Physiol 1987; 252: E209-217.
65. Andreani D. Lights and shadows of insulin treatment seen by a senior diabetologist. Exp Clin Endocrinol Diabetes 1999; 107: S1-5.
66. Herring R, Jones RH, Russell-Jones DL. Hepatoselectivity and the evolution of insulin. Diabetes Obes Metab 2014; 16: 1-8.
67. Henry RR, Mudaliar S, Ciaraldi TP etal. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. Diabetes Care 2014; 37: 2609-2615.
68. Nørgård K, Jensen T, Skøtt P etal. Effect of insulin on renal haemodynamics and sodium handling in healthy subjects. Scand J Clin Lab Invest 1991; 51: 367-376.
69. Hendriksen KV, Jensen T, Oturai P etal. Effects of insulin detemir and NPH insulin on renal handling of sodium, fluid retention and weight in type 2 diabetes. Diabetologia 2012; 55: 46-50.